Ran Friedman

The paper develops a computational model to evaluate combination treatments of type II Abl1 inhibitors and asciminib, introducing ERICcombo to assess synergy and effectiveness at patient-relevant concentrations.

The paper develops a computational model to study drug resistance in Abl1 inhibitors for CML, finding that inhibitory reduction prowess better predicts resistance than traditional metrics.

The paper uses femtosecond X-ray diffraction to study atomic displacements in bovine trypsin crystals, showing correlated movements influenced by THz pulses and atomic type.